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Abstract
Background: Uridine is a therapy for hereditary orotic aciduria and is being investigated in other disorders caused by
mitochondrial dysfunction, including toxicities resulting from treatment with nucleoside reverse transcriptase inhibitors in
HIV. Historically, the use of uridine as a therapeutic agent has been limited by poor bioavailability. A food supplement
containing nucleosides, NucleomaxXH, has been reported to raise plasma uridine to supraphysiologic levels.
Methodology/Principal Findings: Single- and multi-dose PK studies following NucleomaxXH were compared to single-dose
PK studies of equimolar doses of pure uridine in healthy human volunteers. Product analysis documented that more than
90% of the nucleoside component of NucleomaxXH is in the form of triacetyluridine (TAU). Single and repeated dosing with
NucleomaxXH resulted in peak plasma uridine concentrations 1–2 hours later of 150.9639.3 mM and 161.4631.5 mM,
respectively, levels known to ameliorate mitochondrial toxicity in vitro.C max and AUC were four-fold higher after a single
dose of NucleomaxXH than after uridine. No adverse effects of either treatment were observed.
Conclusions/Significance: NucleomaxXH, containing predominantly TAU, has significantly greater bioavailability than pure
uridine in human subjects and may be useful in the management of mitochondrial toxicity.
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Introduction
Uridine, a pyrimidine nucleoside that plays an essential role in
the synthesis of RNA and other key physiologic processes [1], has
been used as a treatment for patients with hereditary orotic
aciduria for more than four decades. The therapeutic potential of
uridine has also been assessed in a diverse group of clinical
disorders including cystic fibrosis, liver dysfunction, chemotherapy
toxicity, pervasive developmental delay, schizophrenia, epilepsy,
and diabetes-induced peripheral neuropathy [2]; and, recently, as
a treatment for mitochondrial dysfunction associated with
treatment with nucleoside reverse transcriptase inhibitors in
patients with HIV infection [3–6].
Circulating levels of uridine are tightly regulated, in the range of
3–8 mM, both by the liver, which synthesizes and degrades
uridine, and by erythrocytes that store UDP-glucose, which may
be catabolized to provide glucose and uridine [2]. Uridine is
absorbed from the gastrointestinal tract via facilitated diffusion or
specific uridine transporters [7]. Historically, the use of uridine as
a therapeutic agent has been limited by poor bioavailability. In a
pharmacokinetic (PK) study of orally-administered uridine, the
maximum tolerated dose was 10–12 g/m
2 for a single dose and
5 g/m
2 for a multiple-dose regimen (every 6 hours for 3 days),
resulting in peak serum uridine concentrations of 60–80 mM after
a single dose and a steady-state serum uridine level of 50 mM after
multiple doses [8]. The dose-limiting side effect was diarrhea.
Recently, administration of NucleomaxXH, a food supplement
that contains approximately 6 g of nucleosides (the equivalent of
about 3.5 g/m
2 in an average-sized male), achieved higher peak
uridine levels (100–150 mM) during a single dose PK study [9]
than were achieved in prior studies using uridine. NucleomaxXH is
apparently well-tolerated. Although these results suggest that the
formulation of uridine in NucleomaxXH may have enhanced
bioavailability, the differences in plasma uridine levels achieved in
studies of uridine and those of NucleomaxxH could also be
explained by the fact that different analytic techniques and study
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nucleoside components of NucleomaxXH and compared the PK
profiles achieved following equimolar doses of the pyrimidine
nucleosides provided by NucleomaxXH to that of pure uridine in
healthy human volunteers. In addition, because the optimal dosing
regimen of NucleomaxXH is not known, we also performed
multiple-dose PK studies using NucleomaxXH to determine
whether repeated dosing had a cumulative effect on plasma
uridine levels.
Methods
Ethics Statement
All studies were approved by the Clinical and Translational
Sciences Institute Clinical Research Center (CRC) at San
Francisco General Hospital Advisory Committee and the
University of California San Francisco Institutional Review Board.
All subjects provided written informed consent.
Product Analysis
To determine the total nucleoside content in NucleomaxXH, the
contents of 10 sachets, each containing 36 gm of NucleomaxXH,
were combined, homogenized and passed through a 60 mesh
sieve. Nucleosides were extracted in aqueous solution containing
ascorbic acid and quantified by reversed-phase high performance
liquid chromatography (HPLC) with ultraviolet (UV) detection.
Laboratory validation was performed to determine the repeat-
ability, accuracy, selectivity, ruggedness and linearity of the
method.
To determine the repeatability precision, four replicate test
preparations of the NucleomaxXH product were prepared and
analyzed on three separate days, for a total of 12 replicate
preparations. The within-day, between-day, and total repeatability
precision of the uridine and TAU content were calculated from
the results. Accuracy was determined by spiking a placebo (a
mixture of casein and sucrose) with uridine and TAU at three
different concentrations in triplicate and determining the recovery.
In addition, NucleomaxXH product was spiked with TAU and
uridine in triplicate, and the recovery of each was determined.
The identities of the uridine and TAU in the NucleomaxXH
material were confirmed by liquid chromatography-mass spec-
trometry/mass spectrometry (LC-MS/MS) on two separate
systems. The primary study was conducted on a Waters 2695
solvent delivery system, Waters 2996 photodiode array detector,
and Waters/Micromass Quattro Micro LC/MS/MS system.
Chromatography was performed using gradient elution with
mobile phases of 0.1% formic acid in water and methanol on a
Sunfire 3.5 mm, 2.16150 mm column and a mobile phase flow
rate of 0.25 mL/min. Spray chamber conditions were: electron
spray ionization (ESI) positive mode, cone voltage 35 KV, source
temperature 120uC, desolvation temperature 300uC, and cone gas
flow rate 50 L/min.
A secondary study to confirm TAU identity in NucleomaxXH
was performed on a Varian 1200L HPLC-MS/MS with ESI
source operated in positive mode using a C18 column and similar
mobile phase conditions as the primary study.
Pharmacokinetic studies of NucleomaxXH
Single- and multiple-dose PK studies of NucleomaxXH,
supplied by PharmaNord (Spanga, Sweden), were performed in
eight healthy volunteers (four men, four women) who were
hospitalized in the CRC at San Francisco General Hospital for 7
days and fed a constant diet. The ingredients and nutritional
composition of NucleomaxXH were provided by the manufacturer
(Tables S1 and S2). On Day 1, one sachet (36 g) of NucleomaxXH
was mixed with 300 mL of liquid and was administered as a single
dose. All blood samples were collected on ethylene diamine
tetraacetic acid. For the single-dose PK studies, plasma uridine
levels were measured just prior to and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8,
12, 16, 20, and 24 hours following administration of Nucleo-
maxXH. On Days 2–6, subjects were dosed with a single sachet
every 8 hours, and uridine was measured 1, 2, 4, and 8 hours after
each dose. On Day 7, the full-scale single-dose PK study was
repeated.
Pharmacokinetic studies of pure uridine
Single-dose PK studies using pure uridine (RG2417), supplied
by Repligen Corporation (Waltham, MA), were also performed
using a protocol identical to that described above in eight healthy
volunteers (four men, four women) who were hospitalized
overnight in the CRC. Based on the results of the independent
product analysis described above, we administered RG2417,
dissolved in water, in an amount designed to provide an equimolar
amount of total nucleosides to that contained in a single sachet of
NucleomaxXH (4.15 gm RG2417 [Repligen, Inc., Waltham, MA],
containing 1.70610
22 mol of uridine). The identical protocol used
for the single-dose PK study of NucleomaxXH was employed.
Plasma uridine assays
40 mM of
13C9 uridine (Spectra Stable Isotopes, Columbia,
MD) as an internal standard was added to 50 mL of plasma, which
was subsequently denatured with 1 mL of 2-propanol. Superna-
tants were isolated after 5 minutes of centrifugation to pellet
precipitates (5000 rpm, 4uC). Samples were then evaporated to
dryness using a Speedvac for 60 minutes, resuspended in 1 mL of
10 mM ammonium formate, purified through a 0.02 mM What-
man anotop syringe filter, and frozen at 220uC until LC-MS
analyses were performed.
Samples were introduced on a SpectraSystem P4000 HPLC
system equipped with an AS3000 SpectraSystem autosampler
(Thermo Electron, San Jose, CA, USA). 50 mL of sample
containing uridine and internal standard were chromatographed
on a 4.0 mm 6150 mm Supelco Discovery HSF5 5 micron
column fitted with an HSF5 guard column, 4.0 mm 620 mm
(Supelco, Bellefonte, Pennsylvania, USA). The column was first
conditioned by a mobile phase of 10 mM ammonium formate in
HPLC water at a flow rate of 0.7 mL/min for 4 minutes. Then the
isocratic LC method used a mobile phase of 10 mM ammonium
formate in methanol at a flow rate of 0.7 mL/min for 3 minutes.
The column was reconditioned by 10 mM ammonium formate in
HPLC water at a flow rate of 0.7 mL/min for 4.9 minutes before
the next injection. The LC effluent from the sample injections was
directed to the APCI source on the TSQ 7000.
Selected Reaction Monitoring (SRM) on the Thermo Finnigan
TSQ 7000 (Thermo Electron, San Jose, CA, USA) was used for
detection of both uridine and
13C9 uridine as internal standard.
Mass spectrometer parameters for the LC/MS/MS assay were as
follows: Ion source atmospheric pressure chemical ionization; ion
polarity positive; sheath gas pressure 60 psi; capillary temperature
250uC; vaporizer temperature 450uC; corona discharge current
(uA) 4.0. For uridine, SRM parameters on the TSQ 7000 were:
SRM transition 245.1R113.0; collision energy 21; scan time 0.1.
For
13C9 uridine, SRM parameters on the TSQ 7000 were: SRM
transition 254.1R 117.0; collision energy 19; scan time 0.1.
Pharmacokinetic and statistical analyses
For PK analyses, baseline levels of plasma uridine measured
prior to administration of either NucleomaxXH or pure uridine
Uridine Bioavailabilty
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endogenous levels of uridine. The Day 1 baseline uridine level was
subtracted from values in the Day 7 analysis, rather than Day 7
baseline uridine levels, which were higher due to prior exogenous
administration of NucleomaxXH. PK parameters were determined
using a noncompartmental model and the ‘‘best fit’’ lambda z
calculation method (WinNonlin, Pharsight Corp., Mountain View,
CA). AUC was calculated using the trapezoidal method. In order
to explain the observed differences in results obtained in the men
and women, analyses were also performed adjusting for lean body
mass as determined by dual energy X-ray absorptiometry
(Hologics Discovery Wi, Waltham, MA). PK parameters obtained
for NucleomaxXH on Days 1 and 7 were compared using a paired
t-test. Student’s t-test was used to compare the Day 1 PK
parameters of NucleomaxXH and uridine (RG2417).
Results
Product Analysis
Each sachet of NucleomaxXH contained 0.58 g (1.61% by
weight) uridine and 5.4 g (15.0%) 29,39,59-tri-O-acetyluridine
(Figure 1) as determined by HPLC-UV. The analytical method
for the determination of uridine and TAU was validated according
to Association of Official Analytical Chemists International
guidelines for single-laboratory validation for accuracy, precision,
selectivity, linearity/range, ruggedness, and limits of detection and
quantitation. The identity of TAU was verified by HPLC with
tandem mass spectroscopy. Uridine and TAU recoveries from
NucleomaxXH were 98.2% –104.8%, and 98.3–101.5%, respec-
tively, and repeatability precision was 2.43% relative standard
deviation (RSD) for uridine, and 2.00% RSD for TAU. When the
uridine and TAU content are combined, we calculated that each
sachet of NucleomaxXH contained the equivalent of
1.70610
22 mol of total uridine.
Subjects
Separate PK studies were performed using NucleomaxXH and
pure uridine. There were no significant differences in baseline
characteristics between the men who participated in the two
studies (Table 1). Among the women, those participating in the
NucleomaxXH study had a slightly lower lean body mass (36.6 vs.
39.8 kg, p=0.03) than in the uridine group. No adverse effects of
either NucleomaxXH or pure uridine were reported by the study
volunteers.
Uridine pharmacokinetics following administration of
NucleomaxXH
At baseline (t=0 on Day 1), mean plasma uridine level was
4.7 uM, consistent with known physiologic concentrations of this
nucleoside [2]. Plasma uridine levels increased to similar maximal
concentrations (.150 mM) 1–2 hours after dosing (Table 2) on
both Day 1 and Day 7. The half-life of uridine after cumulative
dosing was longer than that observed after a single dose (5.361.4
vs. 3.460.8 hours, p=0.01). Plasma uridine levels at t=0 as well
as mean uridine area under the curve (AUC) and AUC‘ were
greater on Day 7 than on Day 1, but the latter could be attributed
to the higher baseline level of uridine on Day 7. With both the
single- and multi-dose NucleomaxXH regimens, women achieved
higher uridine concentrations than men (Figure 2). When plasma
uridine levels were adjusted for body weight or lean body mass, the
differences between men and women were no longer evident.
Among the men, plasma uridine levels were higher on Day 7
compared with Day 1 at all time points (Figure 3a), but among the
women, there were no significant differences in the PK profiles on
days 1 and 7 (Figure 3b).
Uridine pharmacokinetics following administration of
pure uridine (RG2417)
Mean plasma uridine level prior to drug administration (t=0)
was similar in both PK studies (4.161.4 vs. 4.762.1 uM, for the
uridine and NucleomaxXH studies, respectively; p=NS). When
the single-dose uridine PK profile of NucleomaxXH (containing
predominantly TAU) was compared with that of pure uridine
using the same PK protocol and laboratory assay, four-fold greater
bioavailability was observed with NucleomaxXH. The maximal
uridine concentration, AUC, and AUC‘ were significantly higher
in both men and women (Table 2 and Figure 4). The mean
maximal concentration of uridine after administration of pure
Figure 1. Structures of Uridine and 29,39,59-Tri-O-acetyluridine (TAU).
doi:10.1371/journal.pone.0014709.g001
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NucleomaxXH (p,0.0001), also occurring 1–2 hours after dosing.
The half-life for pure uridine was longer than that for
NucleomaxXH (4.661.2 vs. 3.460.8 hours, p=0.05).
Discussion
Both single and repeated dosing with NucleomaxXH resulted in
peak plasma uridine concentrations .150 mM, levels known to
ameliorate mitochondrial toxicity in vitro, without any adverse
effects. Women achieved higher uridine concentrations than men,
likely attributable to their smaller body size. The men demon-
strated higher uridine levels after six days of cumulative
administration of NucleomaxXH compared with Day 1, but the
women showed no further rises in uridine concentration. Given
the small number of subjects, no definitive conclusions can be
made regarding these apparent gender differences in the uridine
bioavailability of NucleomaxXH, but these results invite further
study. Cmax and AUC were four-fold higher after administration of
a single dose of NucleomaxXH than that found after an equimolar
amount of pure uridine (RG2417). The finding that .90% of the
nucleoside component of NucleomaxXH is in the form of TAU,
rather than uridine, suggests that TAU has much greater
bioavailability than pure uridine.
To our knowledge, this is the first study to demonstrate
enhanced bioavailibility of TAU compared with uridine in
humans. In mice, the relative bioavailability of plasma uridine
from orally administered TAU was 7-fold greater than that
achieved by an equimolar amount of oral uridine [10]. The
increased bioavailability of TAU is likely due to its molecular
structure, since the additional acetyl groups result in greater
lipophilicity and, therefore, enhanced gastrointestinal tract ab-
sorption [11]. Unlike uridine, TAU does not require a pyrimidine
transporter for absorption. In addition, TAU is resistant to
catabolism by uridine phosphorylase [12]. It is converted into
uridine by intestinal and plasma esterases cleaving the acetyl
groups, allowing sustained tissue delivery of uridine [11].
Our findings in the single-dose PK study of NucleomaxXH are
consistent with those previously reported by Venhoff et al. [9].
Even though subjects were studied and samples were analyzed in
different laboratories, key results were remarkably similar. In our
study and the study by Venhoff et al., baseline uridine
concentrations were 4.7 and 5.6 mM and maximal uridine
Table 1. Subject Characteristics in the PK studies of NucleomaxXH and uridine (RG2417).
Men NucleomaxXH (n=4) Uridine(n=4)
Age (years) 39.5 (12.8) 30.0 (7.9)
Weight (kg) 80.8 (7.3) 87.2 (7.8)
BMI (kg/m
2) 26.1 (2.7) 26.0 (3.1)
Total fat (kg) 19.4 (5.3) 17.4 (4.7)
Total lean (kg) 57.3 (4.2) 65.4 (8.3)
Percent fat mass (%) 24.2 (5.1) 20.3 (5.9)
Women (n=4) (n=4)
Age (years) 30.3 (9.5) 31.3 (12.0)
Weight (kg) 60.1 (6.6) 60.0 (11.0)
BMI (kg/m
2) 24.0 (3.6) 22.0 (2.4)
Total fat (kg) 20.5 (4.2) 17.1 (5.9)
Total lean (kg) 36.6 (3.0) 39.8 (5.4)*
Percent fat mass (%) 34.3 (4.1) 28.3 (4.9)
*p=0.03 vs women studied with NucleomaxXH.
Data are presented as mean (SD).
doi:10.1371/journal.pone.0014709.t001
Table 2. PK parameters for NucleomaxXH (Day 1 &7) and an equimolar amount of pure uridine (RG2417).
NucleomaxXH Uridine
Day 1 Day 7 p-value Day 1 p-value*
C0 (mM) 4.7 (2.1) 31.1 (4.9) ,0.0001 4.1 (1.4) NS
Cmax (mM) 150.9 (39.3) 161.4 (31.5) NS 36.1 (11.3) ,0.0001
tmax (h) 1.3 (0.5) 1.5 (0.5) NS 1.9 (0.9) NS
t1/2 (h) 3.4 (0.8) 5.3 (1.4) 0.01 4.6 (1.2) 0.05
AUC (mM/h) 602.5 (143.3) 786.4 (115.9) 0.002 143.0 (57.7) ,0.0001
AUCinf (mM/h) 620.8 (140.5) 843.6 (120.9) 0.0003 164.1 (59.4) ,0.0001
AUCinf adjusted for baseline (mM/h) 599.5 (140.0) 606.2 (102.8) NS 135.4 (64.5) ,0.0001
*vs. Day 1 of NucleomaxXH.
Data are presented as mean (SD).
doi:10.1371/journal.pone.0014709.t002
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maximal concentration was 1.3 h in both studies. We extend these
previous findings to include pharmacokinetics of uridine after the
administration of multiple doses of NucleomaxXH (three times per
day) and after cumulative dosing for six days. The rapid, dramatic
rises in plasma uridine observed after administration of Nucleo-
maxXH contrast with those seen with equimolar amounts of pure
uridine, highlighting the potentially benefical pharmacokinetics of
this dietary supplement.
Positive effects of uridine on mitochondrial function and
oxidative metabolism have been demonstrated in both cell culture
and animal models. In mammalian cells artificially depleted of
mtDNA (rho cells) [13] as well as in fibroblasts from humans with
decreased levels of mtDNA (due to a nuclear genetic defect in
respiratory-chain function) [14], uridine and pyruvate supplemen-
tation are required to maintain growth. Ehrlich ascites tumor cells
grown in glucose-deprived medium supplemented with uridine
increased oxygen uptake by 50% and reduced lactate production
to 10% of that in control cells [15]. ATP production was
unchanged, despite a reduction in glycolysis, due to an increase in
oxidative pathways. Uridine also increased myocardial perfor-
mance, glucose uptake and glycolysis, in addition to diminishing
the disappearance of glycogen and adenine nucleotides from
hypoxic rabbit hearts [16].
Mitochondrial dysfunction has been proposed as the unifying
feature of NRTI-induced toxicity in patients with HIV infection.
Because uridine supplementation may favor mtDNA synthesis by
increasing the pyrimidine pool, it has been investigated as a
potential therapy in this setting. Uridine reversed the toxic effects
of zidovudine on colony formation in human bone marrow
progenitor cells without impairing the antiretroviral effect of this
agent [4]. Uridine was also found to prevent zalcitabine-induced
toxicity in PC12 cells, a neuronal model used to study peripheral
neuropathy [5]. In human HepG2-hepatocytes exposed to NRTIs,
uridine normalized cell proliferation, lactate levels, and intracel-
lular lipids by increasing mtDNA levels to about 65% of NRTI-
unexposed control cells [6].
Published data on the effects of uridine on NRTI-induced
toxicity in humans are limited. A single case report described a
remarkable salutary effect of only four days of treatment with
NucleomaxXH, ameliorating the mitochondrial toxicity caused by
stavudine and leading to improvements in myalgias, liver and
muscle enzymes, lactate levels, and steatosis, despite continuing
treatment with stavudine [17]. Recently, a randomized, double-
Figure 2. Single- and multi-dose PK profiles of uridine. (a) PK profile of uridine following a single-dose of NucleomaxXH in all subjects. The
solid squares indicate female subjects, and the open circles indicate male subjects. (b) PK profile of uridine following three doses of NucleomaxXH in
all subjects. The solid squares indicate female subjects, and the open circles indicate male subjects.
doi:10.1371/journal.pone.0014709.g002
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of HIV-associated lipoatrophy reported a significant increase in
limb fat, intra-abdominal fat, and total body fat [18]. Our study,
which demonstrates that the nucleoside content of NucleomaxXH
is predominantly TAU, may explain why such remarkable clinical
results have been obtained with NucleomaxXH as the source of
uridine supplementation. However, the optimal therapeutic dose
and plasma or intracellular uridine levels for treatment of NRTI-
associated toxicity are not known.
Although it remains possible that another component of
NucleomaxXH explains the enhanced bioavailability of uridine,
we were unable to study pure TAU due to its lack of availability.
Moreover, we felt that investigation of NucleomaxXH was more
relevant to current clinical practice since it is already being used by
HIV-infected individuals. Given the considerable interest among
these patients in the use of complementary and alternative
medicine [19], including food supplements, even though scientific
evidence of their efficacy is scarce, there is clearly need for rigorous
scientific studies investigating both the content and the mechanism
of these supplements.
Mitochondrial dysfunction may also play a role in the abnormal
glucose metabolism resulting from NRTI toxicity, and perhaps
diabetes in non-HIV-infected individuals. The proposed mecha-
nism entails reduced oxidative enzyme capacity, thereby increas-
ing lipid accumulation in muscle and liver. These fatty acids and
their metabolites inhibit insulin-stimulated glucose transport,
subsequently leading to insulin resistance [20]. The ATP
generated by oxidative phosphorylation in the mitochondria is
also necessary for glucose sensing and exocytosis of insulin
granules, leading to impaired insulin secretion in the b-cells of
the pancreas [21].
If mitochondrial dysfunction is, indeed, the underlying cellular
defect that explains abnormal glucose metabolism, agents that
enhance mitochondrial function—such as uridine— may improve
glucose homeostasis in this and other insulin-resistant states (e.g.
type 2 diabetes, the metabolic syndrome, polycystic ovary
Figure 3. Comparison of PK profiles of uridine following NucleomaxXH administration on Day 1 and Day 7. (a) The open circles indicate
day 1 (single-dose), and the solid diamonds indicate day 7 (cumulative-dosing) in men. (b) The solid squares indicate day 1 (single-dose), and the
open diamonds indicate day 7 (cumulative-dosing) in women.
doi:10.1371/journal.pone.0014709.g003
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administration of NucleomaxXH, containing predominantly TAU,
was able to overcome prior issues of poor bioavailability with pure
uridine in human subjects with no adverse effects. Given its ability
to raise and sustain supraphysiologic uridine levels, TAU may be
useful in the management of disorders previously treated with
uridine.
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